About E3 ubiquitin-protein ligase TRIM4
E3 ubiquitin-protein ligase TRIM4 (TRIM4) is a protein
from Homo sapiens identified by UniProt accession
Q9C037, 500 residues long.
MolForge cross-references it against 0 known binders and
43 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase TRIM4 |
| UniProt accession | Q9C037 |
| Gene | TRIM4 |
| Organism | Homo sapiens |
| Length | 500 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (43)
Diseases linked to this target (Open Targets).
- serum metabolite measurement · score 0.24
- metabolite measurement · score 0.21
- estrone measurement · score 0.09
- hormone measurement · score 0.08
- hepatocellular carcinoma · score 0.08
- lymphocyte count · score 0.06
- bone density · score 0.06
- neoplasm · score 0.06
- HbA1c measurement · score 0.05
- Ataxia-telangiectasia · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9C037-F1 | alphafold | PREDICTED | 83.37 | — |
Amino-acid sequence (500 residues)
MEAEDIQEEL TCPICLDYFQ DPVSIECGHN FCRGCLHRNW APGGGPFPCP ECRHPSAPAA LRPNWALARL TEKTQRRRLG PVPPGLCGRH WEPLRLFCED DQRPVCLVCR ESQEHQTHAM APIDEAFESY RTGNFDIHVD EWKRRLIRLL LYHFKQEEKL LKSQRNLVAK MKKVMHLQDV EVKNATQWKD KIKSQRMRIS TEFSKLHNFL VEEEDLFLQR LNKEEEETKK KLNENTLKLN QTIASLKKLI LEVGEKSQAP TLELLQNPKE VLTRSEIQDV NYSLEAVKVK TVCQIPLMKE MLKRFQVAVN LAEDTAHPKL VFSQEGRYVK NTASASSWPV FSSAWNYFAG WRNPQKTAFV ERFQHLPCVL GKNVFTSGKH YWEVESRDSL EVAVGVCRED VMGITDRSKM SPDVGIWAIY WSAAGYWPLI GFPGTPTQQE PALHRVGVYL DRGTGNVSFY SAVDGVHLHT FSCSSVSRLR PFFWLSPLAS LVIPPVTDRK
Explore E3 ubiquitin-protein ligase TRIM4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets